

1 **Title:** West African pre-pandemic cross-reactive antibody and cellular responses
2 against SARS-CoV-2

3
4 **Authors:** Bobby Brooke Herrera,¹⁻⁴ Beth Chaplin,⁴ Souleymane MBoup,⁵ Adam
5 Abdullahi,^{6,7} Michelle He,⁴ Sydney M. Fisher,⁴ Sulaimon Akanmu,⁸ Charlotte A Chang,⁴
6 Donald J Hamel,⁴ Ravindra K. Gupta,^{6,7} Phyllis J Kanki⁴

7
8 **Affiliations:**

9 ¹Rutgers Global Health Institute, Rutgers University, New Brunswick, NJ, USA

10 ²Department of Medicine, Division of Allergy, Immunology, and Infectious Diseases, and
11 Child Health Institute of New Jersey, Rutgers Robert Wood Johnson Medical School,
12 Rutgers University, New Brunswick, NJ, USA

13 ³Mir Biosciences, Inc., Dunellen, NJ, USA

14 ⁴Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of
15 Public Health, Boston, MA, USA

16 ⁵Institut de Recherche en Santé de Surveillance épidémiologique et de formation
17 (IRESSEF), Dakar, Senegal

18 ⁶Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID),

19 Cambridge, UK ⁷Department of Medicine, University of Cambridge, Cambridge, UK

20 ⁸Lagos University Teaching Hospital, College of Medicine, University of Lagos, Lagos,
21 Nigeria

22 **Correspondence:** PK, pkanki@hsph.harvard.edu

23 **Abstract**

24 The COVID-19 pandemic had a severe impact globally, yet African populations
25 exhibited unexpectedly lower rates of severe disease and mortality. We investigated the
26 potential role of pre-existing immunity in shaping the epidemiology of COVID-19 in
27 Africa. Leveraging paired plasma and peripheral blood mononuclear cells collected from
28 Senegalese female sex workers prior to the COVID-19 pandemic, we observed
29 substantial levels of pre-existing cross-reactive immunity to SARS-CoV-2, stemming
30 from prior exposure to seasonal human coronaviruses (hCoVs). Our antibody analysis
31 revealed a 23.5% (47/200) seroprevalence rate against SARS-CoV-2 nucleocapsid (N).
32 Of these SARS-CoV-2 N-reactives, 85.1% (40/47), 44.7% (21/47), and 95.7% (45/47)
33 showed antibody reactivity against hCoV-229E or hCoV-OC43 spike (S) and/or N or
34 hCoV-HKU1 S. Our analysis of cellular responses also demonstrated cross-reactivity to
35 SARS-CoV-2 with 82.2% (37/45) and 84.4% (38/45) showing IFN- γ responses against
36 S and N, respectively. These findings suggest that prior hCoV exposure may induce
37 cross-reactive adaptive immunity, potentially contributing to protection against COVID-
38 19. A unique pre-pandemic subject had cross-reactive SARS-CoV-2 S antibodies with
39 detectable neutralization and cellular responses. Our study provides unique insights into
40 the dynamics of hCoV and SARS-CoV-2 immunity in West African populations and
41 underscores the importance of understanding the role of pre-existing immunity in
42 shaping COVID-19 outcomes globally.

43

44

45

46 **Introduction**

47 The first COVID-19 cases were recorded on the African continent in March 2020,
48 yet by the end of the pandemic in May 2023, Africa's reported SARS-CoV-2 infections
49 and deaths constituted only 2-4% of the global disease burden despite being home to
50 ~17% of the world's population. Early projections of the COVID-19 pandemic's impact
51 on Africa predicted massive loss of life. Most African countries lacked adequate
52 healthcare infrastructure, workforce, and equipped facilities to cope with a novel and
53 highly infectious respiratory pathogen. However, other characteristics of most African
54 countries suggested different outcomes from what was seen in resource-rich settings.¹
55 Africa's relatively young population age distribution with lower rates of co-existing
56 morbidities, environmental factors, and pre-existing immunity from exposure to related
57 viruses may explain the unexpected low rates of severe disease and mortality observed
58 in Africa.²

59 In 2020, SARS-CoV-2 emerged as a new human coronavirus, even though
60 worldwide populations were known to be regularly exposed to seasonal human
61 coronaviruses (hCoVs) responsible for the "common cold," including α -coronaviruses
62 (hCoV-229E, hCoV-NL63,) and β -coronaviruses (hCoV-OC43, hCoV-HKU1). Although
63 associated with mild illness, these hCoVs share genetic similarity to the SARS
64 coronaviruses, which include SARS-CoV-1, SARS-CoV-2, and Middle East Respiratory
65 Syndrome (MERS). hCoVs are globally endemic and estimated to be responsible for up
66 to 15-30% of pre-pandemic annual respiratory infections, which are seasonal (e.g., fall
67 and winter) and most prevalent in young children.

68 The widespread circulation of hCoVs with repeated exposure of human
69 populations and shared sequence homology to SARS-CoV-2 led to the suggestion that
70 hCoV immunologic memory could result in cross-reactive cellular and humoral
71 responses that might in part explain the heterogeneity of COVID-19 presenting
72 symptoms and pathogenic outcomes. While not providing sterilizing immunity, pre-
73 existing hCoV immunity could reduce transmission and ameliorate symptoms of the
74 related SARS-CoV-2. Therefore, research has been conducted to determine the role of
75 pre-existing cross-reactive immunity to SARS-CoV-2. Multiple US and European studies
76 described CD4+ T cell reactivity in SARS-CoV-2 unexposed individuals, attributed to
77 pre-existing memory responses to hCoVs.³⁻⁷ In a UK household study, exposed
78 contacts that remained PCR-negative showed significantly higher frequency of cross-
79 reactive ($p=.0139$) and nucleocapsid (N)-specific IL-2 secreting memory T cells
80 ($p=.0355$).³ Swadling et al. in a study of potentially abortive SARS-CoV-2 infection in UK
81 healthcare workers (HCWs) described pre-existing T cell reactivity directed against the
82 early transcribed replication-transcription complex (RTC).⁴ The RTC, consisting of RNA
83 polymerase co-factor non-structural protein 7 (NSP7), RNA polymerase NSP12 and
84 helicase NSP13, is expressed early in the viral life cycle and is highly conserved among
85 members of *Coronaviridae*.⁴ Studies of pre-pandemic samples collected from Africa
86 have also demonstrated cross-reactive T cell responses against several SARS-CoV-2
87 antigens.^{5,6} These studies have led to the hypothesis that prior hCoV infection might
88 provide protective cross-reactive memory, perhaps more likely in younger individuals in
89 whom infections with hCoVs are more prevalent and recent. As described by Lipsitch et
90 al., pre-existing cross-reactive memory T cells could lower respiratory tract viral load

91 thereby limiting the duration and severity of disease with potential to reduce viral
92 spread.⁷

93 Pre-existing antibody studies have also described distinct humoral responses to
94 SARS-CoV-2 associated with prior hCoV infection. Ng et al. described uninfected
95 donors with IgG reactivity to conserved epitopes in the S2 subunit of the SARS-CoV-2
96 spike (S) protein distinct from de novo humoral responses in infected individuals that
97 targeted both S1 and S2 subunits with concomitant IgM and IgA responses.⁸ Multiple
98 studies conducted in the US and Europe have identified antibodies to hCoVs (OC43)
99 that were associated with lower risk of severe COVID-19.^{9, 10}

100 Over the course of the COVID-19 pandemic in Africa, studies based on SARS-
101 CoV-2 antibody detection described high prevalence rates of infection, in contrast with
102 surveillance data.¹¹ Yet, even with anticipated underreporting, severe COVID-19 cases
103 and mortality remained unexpectedly low.¹² While multiple factors are likely to contribute
104 to the capacity of individuals to generate cross-reactivity, it is possible that the order and
105 composition of different infections may play a role in determining the efficacy of the
106 immune response in preventing symptomatic or severe COVID-19. Currently, high rates
107 of SARS-CoV-2 infection and COVID-19 vaccine exposure globally challenge the ability
108 to investigate cross-reactive responses in individuals who have not been exposed to
109 SARS-CoV-2. While our research group has reported on SARS-CoV-2 immune
110 responses in Nigeria,⁵ in this study we leveraged paired plasma and peripheral blood
111 mononuclear cell (PBMC) samples collected in Senegal, West Africa prior to the COVID-
112 19 pandemic. Our objectives were to measure hCoV seroprevalence rates and to
113 characterize the pre-existing cross-reactive antibody and cellular responses to SARS-

114 CoV-2 in our pre-pandemic West African samples. The aim was to understand whether
115 and how pre-existing hCoV immunity might confer protection against severe COVID-19
116 disease in Africa.

117

118 **Methods**

119

120 Human samples:

121 The plasma and PBMC archive was developed from our multi-decade
122 prospective cohort study of HIV-1 and HIV-2 in Senegalese female sex workers
123 (FSWs), followed from 1986-2010.¹³⁻¹⁵ Self-identified FSW routinely visiting a health
124 care clinic in Dakar provided blood samples to test for multiple sexually transmitted
125 infections, including HIV-1 and HIV-2 and were examined clinically; excess blood
126 samples were de-identified and archived with their corresponding clinical data. More
127 than 80% of women sampled were HIV negative and most had paired plasma and liquid
128 nitrogen preserved PBMCs with accompanying clinical and immunologic data at more
129 than 2 timepoints. The viability and functional integrity of these cryopreserved PBMCs
130 have been previously demonstrated in our studies of HIV and flavivirus T-cell
131 immunity.¹⁶⁻¹⁸ The plasma and PBMC samples tested for this study were collected from
132 2004 to 2005. At the time of the original study, all women provided informed consent for
133 the collection and archiving of samples and corresponding data; ethical clearance from
134 the Harvard Institutional Review Board (IRB) and the research ethics committee at
135 Chiekh Anta Diop University, Dakar, Senegal were obtained. All archived samples and
136 corresponding data were anonymized, and as such this secondary analysis did not

137 constitute human subject research by institutional guidelines and regulations which
138 follow the Federal Policy for Protection of Human Subjects.

139 Virion-based immunoblots:

140 We screened plasma samples by immunoblot assay on virion preparations from
141 SARS-CoV-2. Briefly, Vero E6 cells or susceptible cell line were infected with SARS-
142 CoV-2 (Isolate USA-WA1/2020, BEI Resources NR-52281) or hCoVs (OC43, NL63,
143 229E, BEI Resources NR-5621, 470 and 52726, respectively) and propagated for five
144 days. Supernatants were clarified at 10,000g for 20min at 4°C, precipitated with PEG-
145 8000 and NaCl, and then resolved by sucrose gradient ultracentrifugation at 170,000g
146 for 90min at 4°C. Viral pellets were lysed with complete NP40 buffer containing
147 protease inhibitors. Viral lysates were added to nonreducing buffer (final concentrations
148 of 2% SDS, 0.5 M Tris pH 6.8, 20% glycerol, 0.001% bromophenol blue) and subjected
149 to 12% PAGE and Western blot analysis using patient serum (1:250) as primary
150 antibody and anti-human IgG horseradish peroxidase (HRP) (1:2,000; ThermoFisher
151 Scientific, Waltham, MA) as secondary antibody. Visualization was performed using
152 Metal Enhanced DAB Substrate Kit (ThermoFisher Scientific, Waltham, MA) per the
153 manufacturer's instructions.

154 RecomLine SARS-CoV-2 IgG (Mikrogen)^{19, 20} is a CE-marked immunoblot assay
155 which determines the IgG responses towards the recombinant N antigens of the
156 seasonal hCoV 229E, OC43, NL63 and HKU-1 in parallel to SARS-CoV-2 N, receptor-
157 binding domain (RBD), and S1 antigens.

158

159 ELISPOT assay:

160 ELISPOT assays were conducted as described previously^{16, 21, 22}. In brief,
161 200,000 PBMCs per well were seeded in duplicate into 96-well plates coated with anti-
162 human IFN- γ (Becton Dickinson (BD), Franklin Lakes, NJ). The cells were stimulated
163 with fusion proteins consisting of a modified version of the *Bacillus anthracis* lethal
164 factor (LFn) and SARS-²¹CoV-2 S or N ((Mir Biosciences, Inc., Dunellen, NJ) and either
165 a negative (LFn alone, Mir Biosciences, Inc., Dunellen, NJ) or positive (PHA,
166 ThermoFisher, Waltham, MA) control at 37°C with 5% CO₂ for 24 hours. LFn has been
167 shown to transport protein cargoes into the cell cytosol for MHC Class I and II
168 processing, inducing T cell responses.^{16, 21, 22} After incubation, plates were washed
169 followed by incubation for 2 hours at room temperature with a secondary antibody (BD,
170 Franklin Lakes, NJ). Subsequently, plates were washed and incubated with streptavidin
171 (BD, Franklin Lakes, NJ) for 1 hour at room temperature. Finally, plates were washed
172 and incubated with substrate (BD, Franklin Lakes, NJ) for 30 minutes. IFN- γ spot
173 forming cells (SFC) were counted using the ImmunoSpot S6 Ultra M2 Analyzer^{16, 21, 22}
174 (ImmunoSpot, Shaker Heights, OH)

175 **Virus neutralization titer analyses**

176
177 Pseudotype virus neutralization assay was performed on Hela-ACE2 cells using SARS-
178 CoV-2 spike pseudotype virus (PV) expressing luciferase as previously described.^{23, 24}
179 Briefly, dried plasma spots were eluted and heat inactivated at 54°C for 1 hour,²⁵ and
180 incubated with PVs at 37°C for 1 hour prior to addition of Hela-ACE2 cells. The plasma
181 dilution/virus mix was incubated for 48 hours in a 5% CO₂ environment at 37°C, and

182 luminescence was measured using the Bright-Glo Luciferase assay system (Promega
183 UK, United Kingdom). Neutralization was calculated relative to the virus and cell only
184 controls. Data was analyzed in GraphPad Prism v9.3.1 where 50% neutralization (ID₅₀)
185 values were calculated and the limit of detection for neutralization was set at ID₅₀ of 20
186 units.

187 **Statistics**

188 Bivariate analyses explored associations between select demographic
189 characteristics of the women with available data and SARS-CoV-2 N-reactive
190 immunoblot results. Demographic characteristics included: year of sampling, age at
191 sampling, neighborhood, ethnicity, country of origin, marital status, religion, education,
192 and total children. The chi-square test was used to obtain p-values to detect statistically
193 significant associations, and Fisher's exact test for categories with observed
194 frequencies ≤ 5 .

195

196 **Results**

197

198 *Pre-pandemic cross-reactive SARS-CoV-2 antibody responses and hCoV*
199 *seroprevalence rates*

200

201 Pre-pandemic plasma samples (n=200) from the Senegalese FSW cohort were
202 analyzed for the presence of antibodies directed against SARS-CoV-2 S and/or N. 152
203 of 200 (76%) were negative, while 47 (23.5%) showed reactivity to SARS-CoV-2 N,

204 suggestive of prior exposure to hCoVs (Fig. 1, Fig. 2A). To determine hCoV
205 seroprevalence rates, the 47 samples reactive to SARS-CoV-2 N-only were analyzed
206 for antibodies directed against hCoV-229E S and N, hCoV-OC43 S and N, and hCoV-
207 HKU1 S. Of the samples tested, 37 (78.7%) samples showed reactivity to hCoV-229E
208 S_±N, 7 (14.9%) to hCoV-OC43 S_±N, and 45 (95.7%) to hCoV-HKU1 S (Fig. 1, Fig. 2B-
209 D). Of the 37 hCoV-229E S_±N samples, 30 (81.1%) were reactive to S+N, while 7
210 (18.9%) were reactive to S-only. Of the 7 hCoV-OC43 S_±N samples, 6 (85.7%) were
211 reactive to S+N, while 1 (14.3%) was reactive to S-only. Of note, 36 out of the 47
212 samples (76.6%) were reactive to both hCoV-229E S and hCoV-HKU1 S
213 (Supplementary Fig. 1). Only 6 (12.8%) were reactive to S of hCoV-229E, hCoV-OC43,
214 and hCoV-HKU1 (Supplementary Figs. 2-3).

215

216 *Risk factor analysis*

217 Bivariate analysis of risk factors associated with SARS-CoV-2 N antibody
218 reactivity included: year of sampling, age at sampling, neighborhood, ethnicity, country
219 of origin, marital status, religion, education, and total children. There was a potential
220 association between SARS-CoV-2 N-reactive and age >44 years ($p=0.078$) and with
221 having ≥ 3 children ($p=0.044$) (Table 1). Older age had a strong positive correlation with
222 having more children.

223

224 *Pre-pandemic cross-reactive T-cell responses to SARS-CoV-2*

225

226 Of the 47 pre-pandemic samples that showed antibody reactivity to SARS-CoV-2
227 N-only and also antibody reactivity to hCoV S+N/S, 45 paired PBMCs were available,
228 along with 21 paired PBMCs from negative controls, and were analyzed for cross-
229 reactive IFN- γ cellular responses against SARS-CoV-2 S and N. Among SARS-CoV-2
230 N-reactives, 37 (82.2%) showed IFN- γ reactivity against SARS-CoV-2 S (Fig. 3A-B)
231 while 9 (19.6%) were negative. Similarly, 38 (84.4%) showed IFN- γ reactivity against
232 SARS-CoV-2 N (Fig. 3C-D) while 8 (17.4%) were negative. Among the 21 antibody
233 negative controls, 3 (14.3%) demonstrated weak IFN- γ cellular reactivity against both
234 SARS-CoV-2 S and N.

235

236 *Evidence for pre-pandemic SARS-CoV-2 variant*

237

238 In our initial serology, a single sample collected from a FSW in November 2004
239 demonstrated strong antibody reactivity to both SARS-CoV-2 S and N (Fig. 1A).
240 Longitudinal antibody analysis of 6 samples collected from this individual between 1997
241 to 2004 was conducted by SARS-CoV-2 immunoblot as well as the Mikrogen assay that
242 detected antibodies against the individual antigens of SARS-CoV-2 (S, RBD, and N) and
243 hCoVs (HKU1, OC43, NL63, and 229E N). Samples collected in 1997 and 2001 showed
244 antibody reactivity to SARS-CoV-2 N-only by immunoblot with weak antibodies against
245 hCoVs, particularly in the 1997 sample (Fig. 4A-B). Seroconversion to SARS-CoV-2 S
246 (2003) and S and RBD (May to November 2004) was observed by both immunoblot and
247 the Mikrogen assay, accompanied with stronger reactivity to hCoV-HKU1 N and hCoV-
248 OC43 N. This seroprofile is unique from our other pre-pandemic serology and may

249 indicate exposure to a novel variant – one more closely related to SARS-CoV-2.
250 Additionally, longitudinal cellular responses were analyzed between 1997 and 2004. In
251 1997, this individual only had cellular responses against SARS-CoV-2 N. By 2001, this
252 individual had cellular responses against both SARS-CoV-2 S and N that persisted
253 throughout 2004 (Fig. 4C). Sequential analysis of SARS-CoV-2 neutralization revealed
254 no detectable neutralization response against SARS-COV-2 wild-type (Wu-1 614G) in
255 samples collected in 1997 and 2001 but showed detectable neutralization response in
256 samples collected in October 2003 (ID₅₀ titer=281.3) with waning responses observed in
257 May 2004 (ID₅₀ titer=195.6); August 2004 (ID₅₀ titer=121.1) and November 2004 (ID₅₀
258 titer=43.3). The observation of detectable responses coincided with seroconversion of S
259 and RBD antibodies reflecting exposure to hCoVs with possible cross-reactive potential
260 due to sequence homogeneity to a SARS-CoV-2 variant. Clinical examination data
261 collected as part of the prospective HIV clinical protocol did not indicate reporting of
262 symptoms or signs of respiratory disease, but the patient was noted to have lost
263 significant (>10%) weight between 2001 to 2003, during which S antibody seroconversion
264 occurred. The patient was also HIV-positive, 43 years of age in 2003, and had 3 living
265 children.

266

267 **Discussion**

268

269 In early 2021, we studied the immune responses in Nigerian healthcare workers
270 (HCWs) at Lagos University Teaching Hospital (n=134) and in Oxford/AstraZeneca
271 COVID-19 vaccine recipients from the general population (n=116) across five local

272 government areas (LGAs) in Lagos state.⁵ Antibodies directed to only SARS-CoV-2 N
273 in the absence of S antibody reactivity were detected in 9.7% (13/134) of HCWs and
274 15.5% (18/116) of the general population. This antibody profile directed to the SARS-
275 CoV-2 N alone was suggestive of pre-existing cross-reactive immunity stemming from
276 prior hCoV infection. To investigate this possibility further, in this study we tested
277 archived plasma samples collected before the COVID-19 pandemic from our FSW
278 cohort in Dakar, Senegal (2004-2005), and observed 23.5% (47/200) of individuals with
279 pre-existing immunity to SARS-CoV-2 N-only (Fig. 1). Further testing demonstrated
280 prior infections with the seasonal hCoVs, providing evidence that the SARS-CoV-2 N-
281 only reactivity resulted from cross-reactivity from prior hCoV exposure (Fig. 1-2). The
282 coronavirus N protein is more conserved than the S protein. As such, previously hCoV
283 exposed individuals can demonstrate cross-reactive N antibodies without cross-reactive
284 S antibodies (Figs. 1-2).^{5, 26}

285 In one of the few studies conducted on samples from Africa prior to the COVID-
286 19 pandemic, Tso et al. reported higher reactivity to hCoV N and S antigens with
287 significantly higher rates of cross-reactivity in Zambia (14.1%) and Tanzania (19%)
288 compared to the US (2.4%).²⁷ In a multi-national study, Pedersen et al. reported higher
289 SARS-CoV-2 N reactivity in Gabon (20/116, 17.2%) compared to reactivity in Canada,
290 Denmark, and Brazil. In samples from Senegal, largely from subjects under 17 years of
291 age, high antibody cross-reactivity to both S and N antigens of SARS-CoV-2 was
292 observed; these samples failed to demonstrate in vitro neutralization.²⁶ Similar to this
293 Senegal study, our study also detected pre-pandemic antibody cross-reactivity to

294 SARS-CoV-2, but we concurrently detected cellular cross-reactivity to support the
295 antibody results.

296 While most investigators study T cell responses to specific antigens using
297 overlapping peptides, we have used full-length antigens or large peptides fused to a
298 modified version of the *Bacillus anthracis* lethal factor (LFn). LFn has been shown to act
299 as a molecular shuttle, transporting antigens of interest into the cytosol for MHC Class I
300 and Class II processing for CD4+ and CD8+ T cell presentation. In the past, we have
301 used LFn to study T cell responses against several viruses, including HIV, Ebola, Zika,
302 dengue, and SARS-CoV-2.^{22-24,18} In our SARS-CoV-2 study of Nigerian HCWs and
303 individuals from the general population, among individuals with SARS-CoV-2 N-only
304 antibodies prior to vaccination, suggestive of prior exposure to hCoV, 81.8% (9/11) had
305 T cell responses to SARS-CoV-2 N. These results provided further evidence that
306 individuals who were previously exposed to hCoVs could have cross-reactive cellular
307 responses against SARS-CoV-2.

308 Cross-reactive T cell responses play a protective role in protection against
309 COVID-19. Cellular responses were shown to map to cross-reactive recognition of
310 SARS-CoV-2 by T cells induced by hCoVs.²⁸⁻³¹ SARS-CoV-2-specific T cells were also
311 able to cross-react with SARS-CoV-1 and MERS-CoV.³²⁻³⁵ Recently, Tarke et al.,
312 demonstrated that pre-pandemic samples collected from healthy adults in the US with
313 confirmed previous exposure to hCoV-NL63 and -OC43 had significant cross-reactive T
314 cell responses to SARS-CoV-2, particularly to conserved regions of SARS-CoV-2 S, N,
315 nsp3, and nsp12.³⁶ Similarly, Namuniina et al. showed that in pre-pandemic samples
316 collected in Uganda, a majority of subjects had both CD4+ and/or CD8+ T cell

317 responses against SARS-CoV-2 S and non-S peptide pools.⁶ This study however did
318 not determine whether pre-existing immunity based on previous exposure to hCoV was
319 responsible for the cross-reactive cellular responses.

320 In the current study using pre-pandemic samples collected from Senegalese
321 FSWs, we show evidence of cellular cross-reactivity to SARS-CoV-2 with 82.2% (37/45)
322 and 84.4% (38/45) of PBMC samples matched to SARS-CoV-2 N antibody reactive
323 plasma samples demonstrating IFN- γ responses against S and N, respectively (Fig. 3).
324 Although these N antibody reactive samples showed no S antibody reactivity, the
325 majority demonstrated cross-reactive cellular responses to both SARS-CoV-2 S and N,
326 suggesting that cellular responses against this less conserved region may be more
327 sustained over time than humoral responses. Among the SARS-CoV-2 negative
328 controls, a majority (18/21, 85.7%) did not have cellular responses. However, three
329 control individuals showed weak cellular responses against SARS-CoV-2 S and N. This
330 again may reflect the more temporal nature of humoral immunity compared with the
331 longevity of cellular immunity. Additionally, the individual that initially tested antibody
332 positive for SARS-CoV-2 S-only also had sustained cross-reactive cellular responses to
333 SARS-CoV-2 S and/or N from 1997 to 2004 (Fig. 4C) with evidence of sustained albeit
334 waning neutralization responses from 2003 and 2004 (Fig. 4D).

335 It is unknown whether these cross-reactive cellular responses from prior hCoV
336 infection were sustained at levels that would impact the pathogenesis of SARS-CoV-2
337 during the 2020 pandemic. Immunologic memory to antigenically related infections can
338 result in both positive and negative patient outcomes. As described in influenza, the
339 induction of antibody responses to new virus infection can “backboost” responses to

340 preceding heterologous viruses.³⁷ In contrast, prior heterologous responses with
341 reduced functionality may misdirect new responses resulting in negative clinical
342 outcomes, i.e. “original antigenic sin”^{38, 39}, particularly in antigenically shifting viruses
343 such as SARS COV-2. Our results show significant prior hCoV infection with
344 demonstrable antibodies to SARS-CoV-2 N and cellular responses to S and N, which
345 when taken in consideration with low rates of severe COVID-19 disease and mortality in
346 Africa, suggest through indirect association the possibility that prior hCoV infection
347 provides cross-reactive protective immunity in SARS-CoV-2 infection.

348 In our risk factor analysis, we saw potential higher risk of SARS-CoV-2 N
349 reactivity, suggesting previous hCoV infection, in women who were >44 years of age
350 and who had ≥ 3 children. This might be explained by older women having had more
351 children, and therefore increased exposure to respiratory illnesses from young and
352 school-aged children amongst whom susceptibility to infection and transmission may be
353 highest.

354 Our study of pre-pandemic immunologic reactivity to SARS-CoV-2 in Senegal is
355 unique in its assessment of both antibody and cellular responses. However, our study
356 has limitations. We were unable to evaluate the cellular immune responses to hCoVs to
357 verify the proposed source of SARS CoV-2 cross-reactive IFN- γ cellular responses. Our
358 assessment of primary hCoV infection was based on serologic reactivity to hCoV S,
359 which may not be diagnostic of hCoV infection or correlate with hCoV N reactivity or
360 cross-reactivity to SARS-CoV-2 N. We were unable to directly test our hypothesis by
361 demonstrating that a significant fraction of the population possessed antibody and
362 cellular cross-reactive immune responses to SARS-CoV-2 at the time of the pandemic.

363 Also, our study analyzed samples from only adult females, who may have different
364 immune responses than males and children.

365 Altogether, our study uniquely analyzed both antibody and cellular responses in
366 West Africans, demonstrating that pre-existing immunity against hCoVs can induce
367 cross-reactive T cell responses against SARS-CoV-2. The concurrent measurement of
368 cross-reactive immune responses from both the antibody and cellular arms of the
369 adaptive response provides additional support to the hypothesis that pre-existing hCoV
370 adaptive immunity might impact SARS CoV-2 pathogenesis. These data provide
371 valuable insights toward a clearer understanding of the dynamics of SARS-CoV-2
372 disease progression and protection in the West African setting.

373

374 **Role of the funding source**

375 Authors declare that the funder did not have any role in the study design; in the
376 collection, analysis, and interpretation of data; in the writing of the report; and in the
377 decision to submit the paper for publication.

378

379 **References**

380 1. Blanton RE, Mock NB, Hiruy HN, Schieffelin JS, Doumbia S, Happi C, Samuels
381 RJ, Oberhelman RA. African Resources and the Promise of Resilience against COVID-
382 19. *Am J Trop Med Hyg.* 2020. Epub 2020/06/06. doi: 10.4269/ajtmh.20-0470. PubMed
383 PMID: 32500851.

384 2. Uyoga S, Adetifa IMO, Karanja HK, Nyagwange J, Tuju J, Wanjiku P, Aman R,
385 Mwangangi M, Amoth P, Kasera K, Ng'ang'a W, Rombo C, Yegon C, Kithi K, Odhiambo

- 386 E, Rotich T, Orgut I, Kihara S, Otiende M, Bottomley C, Mupe ZN, Kagucia EW,
387 Gallagher KE, Etyang A, Voller S, Gitonga JN, Mugo D, Agoti CN, Otieno E, Ndwiga L,
388 Lambe T, Wright D, Barasa E, Tsofa B, Bejon P, Ochola-Oyier LI, Agweyu A, Scott
389 JAG, Warimwe GM. Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Kenyan
390 blood donors. *Science*. 2020. Epub 2020/11/13. doi: 10.1126/science.abe1916.
391 PubMed PMID: 33177105.
- 392 3. Kundu R, Narean JS, Wang L, Fenn J, Pillay T, Fernandez ND, Conibear E,
393 Koycheva A, Davies M, Tolosa-Wright M, Hakki S, Varro R, McDermott E, Hammett S,
394 Cutajar J, Thwaites RS, Parker E, Rosadas C, McClure M, Tedder R, Taylor GP,
395 Dunning J, Lalvani A. Cross-reactive memory T cells associate with protection against
396 SARS-CoV-2 infection in COVID-19 contacts. *Nat Commun*. 2022;13(1):80. Epub
397 20220110. doi: 10.1038/s41467-021-27674-x. PubMed PMID: 35013199; PMCID:
398 PMC8748880.
- 399 4. Swadling L, Diniz MO, Schmidt NM, Amin OE, Chandran A, Shaw E, Pade C,
400 Gibbons JM, Le Bert N, Tan AT, Jeffery-Smith A, Tan CCS, Tham CYL, Kucykowicz S,
401 Aidoo-Micah G, Rosenheim J, Davies J, Johnson M, Jensen MP, Joy G, McCoy LE,
402 Valdes AM, Chain BM, Goldblatt D, Altmann DM, Boyton RJ, Manisty C, Treibel TA,
403 Moon JC, Investigators CO, van Dorp L, Balloux F, McKnight A, Noursadeghi M,
404 Bertoletti A, Maini MK. Pre-existing polymerase-specific T cells expand in abortive
405 seronegative SARS-CoV-2. *Nature*. 2022;601(7891):110-7. Epub 20211110. doi:
406 10.1038/s41586-021-04186-8. PubMed PMID: 34758478; PMCID: PMC8732273.
- 407 5. Akanmu AS, Herrera BB, Chaplin B, Ogunsola F, Oshibogun A, Onawoga F,
408 John-Olabode S, Akase IE, Nwosu A, Hamel DJ, Chang CA, Kanki PJ. High SARS-

- 409 CoV-2 seroprevalence in Lagos, Nigeria with robust antibody and cellular responses. *J*
410 *Clin Viro Plus.* 2023;3(3):100156. doi: <https://doi.org/10.1016/j.jcvp>. 2023.100156.
- 411 6. Namuniina A, Muyanja ES, Biribawa VM, Okech BA, Ssemaganda A, Price MA,
412 Hills N, Nanteza A, Bagaya BS, Weiskopf D, Riou C, Reynolds SJ, Galiwango RM,
413 Redd AD. Proportion of Ugandans with pre-pandemic SARS-CoV-2 cross-reactive
414 CD4+ and CD8+ T-cell responses: A pilot study. *PLOS Glob Public Health.*
415 2023;3(8):e0001566. Epub 20230816. doi: 10.1371/journal.pgph.0001566. PubMed
416 PMID: 37585383; PMCID: PMC10431628.
- 417 7. Lipsitch M, Grad YH, Sette A, Crotty S. Cross-reactive memory T cells and herd
418 immunity to SARS-CoV-2. *Nat Rev Immunol.* 2020;20(11):709-13. Epub 2020/10/08.
419 doi: 10.1038/s41577-020-00460-4. PubMed PMID: 33024281; PMCID: PMC7537578.
- 420 8. Ng KW, Faulkner N, Cornish GH, Rosa A, Harvey R, Hussain S, Ulferts R, Earl
421 C, Wrobel AG, Benton DJ, Roustan C, Bolland W, Thompson R, Agua-Doce A, Hobson
422 P, Heaney J, Rickman H, Paraskevopoulou S, Houlihan CF, Thomson K, Sanchez E,
423 Shin GY, Spyer MJ, Joshi D, O'Reilly N, Walker PA, Kjaer S, Riddell A, Moore C,
424 Jebson BR, Wilkinson M, Marshall LR, Rosser EC, Radziszewska A, Peckham H,
425 Ciurtin C, Wedderburn LR, Beale R, Swanton C, Gandhi S, Stockinger B, McCauley J,
426 Gamblin SJ, McCoy LE, Cherepanov P, Nastouli E, Kassiotis G. Preexisting and de
427 novo humoral immunity to SARS-CoV-2 in humans. *Science.* 2020;370(6522):1339-43.
428 Epub 20201106. doi: 10.1126/science.abe1107. PubMed PMID: 33159009; PMCID:
429 PMC7857411.
- 430 9. Dugas M, Grote-Westrick T, Merle U, Fontenay M, Kremer AE, Hanses F,
431 Vollenberg R, Lorentzen E, Tiwari-Heckler S, Duchemin J, Ellouze S, Vetter M, Furst J,

- 432 Schuster P, Brix T, Denkinger CM, Muller-Tidow C, Schmidt H, Tepasse PR, Kuhn J.
433 Lack of antibodies against seasonal coronavirus OC43 nucleocapsid protein identifies
434 patients at risk of critical COVID-19. *J Clin Virol.* 2021;139:104847. Epub 20210424.
435 doi: 10.1016/j.jcv.2021.104847. PubMed PMID: 33965698; PMCID: PMC8065244.
- 436 10. Dugas M, Grote-Westrick T, Vollenberg R, Lorentzen E, Brix T, Schmidt H,
437 Tepasse PR, Kuhn J. Less severe course of COVID-19 is associated with elevated
438 levels of antibodies against seasonal human coronaviruses OC43 and HKU1 (HCoV
439 OC43, HCoV HKU1). *Int J Infect Dis.* 2021;105:304-6. Epub 20210223. doi:
440 10.1016/j.ijid.2021.02.085. PubMed PMID: 33636357; PMCID: PMC7901274.
- 441 11. Lewis HC, Ware H, Whelan M, Subissi L, Li Z, Ma X, Nardone A, Valenciano M,
442 Cheng B, Noel K, Cao C, Yanes-Lane M, Herring BL, Talisuna A, Ngoy N, Balde T,
443 Clifton D, Van Kerkhove MD, Buckeridge D, Bobrovitz N, Okeibunor J, Arora RK,
444 Bergeri I, Group USC. SARS-CoV-2 infection in Africa: a systematic review and meta-
445 analysis of standardised seroprevalence studies, from January 2020 to December 2021.
446 *BMJ Glob Health.* 2022;7(8). doi: 10.1136/bmjgh-2022-008793. PubMed PMID:
447 35998978; PMCID: PMC9402450.
- 448 12. Tessema SK, Nkengasong JN. Understanding COVID-19 in Africa. *Nat Rev*
449 *Immunol.* 2021;21(8):469-70. Epub 20210624. doi: 10.1038/s41577-021-00579-y.
450 PubMed PMID: 34168345; PMCID: PMC8222946.
- 451 13. Kanki PJ, Travers KU, S MB, Hsieh CC, Marlink RG, Gueye NA, Siby T, Thior I,
452 Hernandez-Avila M, Sankale JL, et al. Slower heterosexual spread of HIV-2 than HIV-1.
453 *Lancet.* 1994;343(8903):943-6. doi: 10.1016/s0140-6736(94)90065-5. PubMed PMID:
454 7909009.

- 455 14. Marlink R, Kanki P, Thior I, Travers K, Eisen G, Siby T, Traore I, Hsieh CC, Dia
456 MC, Gueye EH, et al. Reduced rate of disease development after HIV-2 infection as
457 compared to HIV-1. *Science*. 1994;265(5178):1587-90. doi: 10.1126/science.7915856.
458 PubMed PMID: 7915856.
- 459 15. Hamel DJ, Sankale JL, Eisen G, Meloni ST, Mullins C, Gueye-Ndiaye A, Mboup
460 S, Kanki PJ. Twenty years of prospective molecular epidemiology in Senegal: changes
461 in HIV diversity. *AIDS Res Hum Retroviruses*. 2007;23(10):1189-96. doi:
462 10.1089/aid.2007.0037. PubMed PMID: 17961103.
- 463 16. Herrera BB, Tsai WY, Chang CA, Hamel DJ, Wang WK, Lu Y, Mboup S, Kanki
464 PJ. Sustained Specific and Cross-Reactive T Cell Responses to Zika and Dengue Virus
465 NS3 in West Africa. *J Virol*. 2018;92(7). Epub 2018/01/13. doi: 10.1128/jvi.01992-17.
466 PubMed PMID: 29321308; PMCID: PMC5972862.
- 467 17. Sarr AD, Lu Y, Sankale JL, Eisen G, Popper S, Mboup S, Kanki PJ, Cao H.
468 Robust HIV type 2 cellular immune response measured by a modified anthrax toxin-
469 based enzyme-linked immunospot assay. *AIDS Res Hum Retroviruses*.
470 2001;17(13):1257-64. doi: 10.1089/088922201750461311. PubMed PMID: 11559425.
- 471 18. Hanson A, Sarr AD, Shea A, Jones N, Mboup S, Kanki P, Cao H. Distinct profile
472 of T cell activation in HIV type 2 compared to HIV type 1 infection: differential
473 mechanism for immunoprotection. *AIDS Res Hum Retroviruses*. 2005;21(9):791-8. doi:
474 10.1089/aid.2005.21.791. PubMed PMID: 16218803.
- 475 19. Bauer G. The variability of the serological response to SARS-corona virus-2:
476 Potential resolution of ambiguity through determination of avidity (functional affinity). *J*

477 Med Virol. 2021;93(1):311-22. Epub 20200715. doi: 10.1002/jmv.26262. PubMed PMID:
478 32633840; PMCID: PMC7361859.

479 20. Struck F, Schreiner P, Staschik E, Wochinz-Richter K, Schulz S, Soutschek E,
480 Motz M, Bauer G. Incomplete IgG avidity maturation after seasonal coronavirus
481 infections. J Med Virol. 2022;94(1):186-96. Epub 20210827. doi: 10.1002/jmv.27291.
482 PubMed PMID: 34427932.

483 21. Herrera BB, Hamel DJ, Oshun P, Akinsola R, Akanmu AS, Chang CA, Eromon
484 P, Folarin O, Adeyemi KT, Happi CT, Lu Y, Ogunsola F, Kanki PJ. A modified anthrax
485 toxin-based enzyme-linked immunospot assay reveals robust T cell responses in
486 symptomatic and asymptomatic Ebola virus exposed individuals. PLoS Negl Trop Dis.
487 2018;12(5):e0006530. Epub 2018/05/26. doi: 10.1371/journal.pntd.0006530. PubMed
488 PMID: 29795572; PMCID: PMC5991402.

489 22. Herrera BB, Tsai WY, Brites C, Luz E, Pedroso C, Drexler JF, Wang WK, Kanki
490 PJ. T Cell Responses to Nonstructural Protein 3 Distinguish Infections by Dengue and
491 Zika Viruses. MBio. 2018;9(4). doi: 10.1128/mBio.00755-18. PubMed PMID: 30087165;
492 PMCID: PMC6083909.

493 23. Abdullahi A, Oladele D, Owusu M, Kemp SA, Ayorinde J, Salako A, Fink D, Ige
494 F, Ferreira I, Meng B, Sylverken AA, Onwuamah C, Boadu KO, Osuolale K, Frimpong
495 JO, Abubakar R, Okuruawe A, Abdullahi HW, Liboro G, Agyemang LD, Ayisi-Boateng
496 NK, Odubela O, Ohihoin G, Ezechi O, Kamasah JS, Ameyaw E, Arthur J, Kyei DB,
497 Owusu DO, Usman O, Mogaji S, Dada A, Agyei G, Ebrahimi S, Gutierrez LC, Aliyu SH,
498 Doffinger R, Audu R, Adegbola R, Mlcochova P, Phillips RO, Solako BL, Gupta RK.
499 SARS-COV-2 antibody responses to AZD1222 vaccination in West Africa. Nat

- 500 Commun. 2022;13(1):6131. Epub 20221017. doi: 10.1038/s41467-022-33792-x.
- 501 PubMed PMID: 36253377; PMCID: PMC9574797.
- 502 24. Abdullahi A, Frimpong J, Cheng MTK, Aliyu SH, Smith C, Abimiku A, Phillips RO,
503 Owusu M, Gupta RK. Performance of SARS COV-2 IgG Anti-N as an Independent
504 Marker of Exposure to SARS COV-2 in an Unvaccinated West African Population. Am J
505 Trop Med Hyg. 2023;109(4):890-4. Epub 20230814. doi: 10.4269/ajtmh.23-0179.
506 PubMed PMID: 37580023; PMCID: PMC10551093.
- 507 25. Wong MP, Meas MA, Adams C, Hernandez S, Green V, Montoya M, Hirsch BM,
508 Horton M, Quach HL, Quach DL, Shao X, Fedrigo I, Zermeno A, Huffaker J, Montes R,
509 Madden A, Cyrus S, McDowell D, Williamson P, Contestable P, Stone M, Coloma J,
510 Busch MP, Barcellos LF, Harris E. Development and Implementation of Dried Blood
511 Spot-Based COVID-19 Serological Assays for Epidemiologic Studies. Microbiol Spectr.
512 2022;10(3):e0247121. Epub 20220525. doi: 10.1128/spectrum.02471-21. PubMed
513 PMID: 35612315; PMCID: PMC9241704.
- 514 26. Pedersen J, Koumakpayi IH, Babuadze G, Baz M, Ndiaye O, Faye O, Diagne
515 CT, Dia N, Naghibosadat M, McGeer A, Muberaka S, Moukandja IP, Ndidi S, Tauil CB,
516 Lekana-Douki JB, Loucoubar C, Faye O, Sall A, Magalhaes KG, Weis N, Kozak R,
517 Kobinger GP, Fausther-Bovendo H. Cross-reactive immunity against SARS-CoV-2 N
518 protein in Central and West Africa precedes the COVID-19 pandemic. Sci Rep.
519 2022;12(1):12962. Epub 20220728. doi: 10.1038/s41598-022-17241-9. PubMed PMID:
520 35902675; PMCID: PMC9333058.
- 521 27. Tso FY, Lidenge SJ, Pena PB, Clegg AA, Ngowi JR, Mwaiselage J, Ngalamika
522 O, Julius P, West JT, Wood C. High prevalence of pre-existing serological cross-

523 reactivity against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) in
524 sub-Saharan Africa. *Int J Infect Dis.* 2021;102:577-83. Epub 20201108. doi:
525 10.1016/j.ijid.2020.10.104. PubMed PMID: 33176202; PMCID: PMC7648883.

526 28. Mateus J, Grifoni A, Tarke A, Sidney J, Ramirez SI, Dan JM, Burger ZC,
527 Rawlings SA, Smith DM, Phillips E, Mallal S, Lammers M, Rubiro P, Quiambao L,
528 Sutherland A, Yu ED, da Silva Antunes R, Greenbaum J, Frazier A, Markmann AJ,
529 Premkumar L, de Silva A, Peters B, Crotty S, Sette A, Weiskopf D. Selective and cross-
530 reactive SARS-CoV-2 T cell epitopes in unexposed humans. *Science.*
531 2020;370(6512):89-94. Epub 20200804. doi: 10.1126/science.abd3871. PubMed PMID:
532 32753554; PMCID: PMC7574914.

533 29. Loyal L, Braun J, Henze L, Kruse B, Dingeldey M, Reimer U, Kern F, Schwarz T,
534 Mangold M, Unger C, Dorfler F, Kadler S, Rosowski J, Gurcan K, Uyar-Aydin Z,
535 Frentsch M, Kurth F, Schnatbaum K, Eckey M, Hippenstiel S, Hocke A, Muller MA,
536 Sawitzki B, Miltenyi S, Paul F, Mall MA, Wenschuh H, Voigt S, Drosten C, Lauster R,
537 Lachman N, Sander LE, Corman VM, Rohmel J, Meyer-Arndt L, Thiel A, Giesecke-Thiel
538 C. Cross-reactive CD4(+) T cells enhance SARS-CoV-2 immune responses upon
539 infection and vaccination. *Science.* 2021;374(6564):eabh1823. Epub 20211008. doi:
540 10.1126/science.abh1823. PubMed PMID: 34465633; PMCID: PMC10026850.

541 30. Nelde A, Bilich T, Heitmann JS, Maringer Y, Salih HR, Roerden M, Lubke M,
542 Bauer J, Rieth J, Wacker M, Peter A, Horber S, Traenkle B, Kaiser PD, Rothbauer U,
543 Becker M, Junker D, Krause G, Strengert M, Schneiderhan-Marra N, Templin MF, Joos
544 TO, Kowalewski DJ, Stos-Zweifel V, Fehr M, Rabsteyn A, Mirakaj V, Karbach J, Jager
545 E, Graf M, Gruber LC, Rachfalski D, Preuss B, Hagelstein I, Marklin M, Bakchoul T,

- 546 Gouttefangeas C, Kohlbacher O, Klein R, Stevanovic S, Rammensee HG, Walz JS.
547 SARS-CoV-2-derived peptides define heterologous and COVID-19-induced T cell
548 recognition. *Nat Immunol.* 2021;22(1):74-85. Epub 20200930. doi: 10.1038/s41590-020-
549 00808-x. PubMed PMID: 32999467.
- 550 31. Le Bert N, Tan AT, Kunasegaran K, Tham CYL, Hafezi M, Chia A, Chng MHY,
551 Lin M, Tan N, Linster M, Chia WN, Chen MI, Wang LF, Ooi EE, Kalimuddin S, Tambyah
552 PA, Low JG, Tan YJ, Bertoletti A. SARS-CoV-2-specific T cell immunity in cases of
553 COVID-19 and SARS, and uninfected controls. *Nature.* 2020;584(7821):457-62. Epub
554 2020/07/16. doi: 10.1038/s41586-020-2550-z. PubMed PMID: 32668444.
- 555 32. Grifoni A, Sidney J, Zhang Y, Scheuermann RH, Peters B, Sette A. A Sequence
556 Homology and Bioinformatic Approach Can Predict Candidate Targets for Immune
557 Responses to SARS-CoV-2. *Cell Host Microbe.* 2020;27(4):671-80 e2. Epub 20200316.
558 doi: 10.1016/j.chom.2020.03.002. PubMed PMID: 32183941; PMCID: PMC7142693.
- 559 33. Habel JR, Nguyen THO, van de Sandt CE, Juno JA, Chaurasia P, Wragg K,
560 Koutsakos M, Hensen L, Jia X, Chua B, Zhang W, Tan HX, Flanagan KL, Doolan DL,
561 Torresi J, Chen W, Wakim LM, Cheng AC, Doherty PC, Petersen J, Rossjohn J,
562 Wheatley AK, Kent SJ, Rowntree LC, Kedzierska K. Suboptimal SARS-CoV-2-specific
563 CD8(+) T cell response associated with the prominent HLA-A*02:01 phenotype. *Proc*
564 *Natl Acad Sci U S A.* 2020;117(39):24384-91. Epub 20200910. doi:
565 10.1073/pnas.2015486117. PubMed PMID: 32913053; PMCID: PMC7533701.
- 566 34. Prakash S, Srivastava R, Coulon PG, Dhanushkodi NR, Chentoufi AA, Tifrea DF,
567 Edwards RA, Figueroa CJ, Schubl SD, Hsieh L, Buchmeier MJ, Bouziane M, Nesburn
568 AB, Kuppermann BD, BenMohamed L. Genome-Wide B Cell, CD4(+), and CD8(+) T

569 Cell Epitopes That Are Highly Conserved between Human and Animal Coronaviruses,
570 Identified from SARS-CoV-2 as Targets for Preemptive Pan-Coronavirus Vaccines. J
571 Immunol. 2021;206(11):2566-82. Epub 20210428. doi: 10.4049/jimmunol.2001438.
572 PubMed PMID: 33911008; PMCID: PMC8722450.

573 35. Rha B, Lively JY, Englund JA, Staat MA, Weinberg GA, Selvarangan R, Halasa
574 NB, Williams JV, Boom JA, Sahni LC, Michaels MG, Stewart LS, Harrison CJ, Szilagyi
575 PG, McNeal MM, Klein EJ, Strelitz B, Lacombe K, Schlaudecker E, Moffatt ME,
576 Schuster JE, Pahud BA, Weddle G, Hickey RW, Avadhanula V, Wikswa ME, Hall AJ,
577 Curns AT, Gerber SI, Langley G. Severe Acute Respiratory Syndrome Coronavirus 2
578 Infections in Children: Multicenter Surveillance, United States, January-March 2020. J
579 Pediatric Infect Dis Soc. 2020;9(5):609-12. doi: 10.1093/jpids/piaa075. PubMed PMID:
580 32556327; PMCID: PMC7337823.

581 36. Tarke A, Zhang Y, Methot N, Narowski TM, Phillips E, Mallal S, Frazier A, Filaci
582 G, Weiskopf D, Dan JM, Premkumar L, Scheuermann RH, Sette A, Grifoni A. Targets
583 and cross-reactivity of human T cell recognition of Common Cold Coronaviruses.
584 bioRxiv. 2023. Epub 20230105. doi: 10.1101/2023.01.04.522794. PubMed PMID:
585 36656777; PMCID: PMC9844015.

586 37. Fonville JM, Wilks SH, James SL, Fox A, Ventresca M, Aban M, Xue L, Jones
587 TC, Le NMH, Pham QT, Tran ND, Wong Y, Mosterin A, Katzelnick LC, Labonte D, Le
588 TT, van der Net G, Skepner E, Russell CA, Kaplan TD, Rimmelzwaan GF, Masurel N,
589 de Jong JC, Palache A, Beyer WEP, Le QM, Nguyen TH, Wertheim HFL, Hurt AC,
590 Osterhaus A, Barr IG, Fouchier RAM, Horby PW, Smith DJ. Antibody landscapes after

591 influenza virus infection or vaccination. *Science*. 2014;346(6212):996-1000. doi:
592 10.1126/science.1256427. PubMed PMID: 25414313; PMCID: PMC4246172.

593 38. Halstead SB, O'Rourke EJ. Antibody-enhanced dengue virus infection in primate
594 leukocytes. *Nature*. 1977;265(5596):739-41. PubMed PMID: 404559.

595 39. Aguilar-Bretones M, Westerhuis BM, Raadsen MP, de Bruin E, Chandler FD,
596 Okba NM, Haagmans BL, Langerak T, Endeman H, van den Akker JP, Gommers DA,
597 van Gorp EC, GeurtsvanKessel CH, de Vries RD, Fouchier RA, Rockx BH, Koopmans
598 MP, van Nierop GP. Seasonal coronavirus-specific B cells with limited SARS-CoV-2
599 cross-reactivity dominate the IgG response in severe COVID-19. *The Journal of clinical*
600 *investigation*. 2021;131(21). doi: 10.1172/JCI150613. PubMed PMID: 34499051;
601 PMCID: PMC8553556.

602



A**B**

Fig. 1. SARS-CoV-2 and hCoVs seroprevalence rates. A) Schematic representation of serology workflow. *, Samples were analyzed against hCoV-HKU1 S only. B) 200 samples were initially tested against SARS-CoV-2 S and N; 47 samples had antibodies against SARS-CoV-2 N-only (blue donut chart). These 47 samples were then tested against hCoV-229E S and N (green donut chart), hCoV-OC43 S and N (purple donut chart), and hCoV-HKU1 S (yellow donut chart).




Fig. 2. SARS-CoV-2 and hCoV antibody cross-reactive in samples collected pre-pandemic. Plasma collected from FSWs prior to the COVID-19 pandemic were subjected to immunoblot analysis. Representative images of immunoblots for samples that had antibodies for A) SARS-CoV-2 N-only or were negative, B) hCoV-229E S+N/S-only, N-only, or were negative, C) hCoV-OC43 S+N, N-only, or were negative, and D) hCoV-HKU1 S or were negative.

Table 1. Associations between baseline characteristics and SARS-CoV-2 nucleocapsid (N) antibody reactivity (N=200¹)

	N reactive		N non-reactive		Chi-square* p-value
	No.	%	No.	%	
Year of sampling					
2004	74	81.3%	17	18.7%	0.142
2005	79	72.5%	30	27.5%	
Age at sampling					
≤44 years	92	76.0%	29	24.0%	0.078
>44 years	22	61.1%	14	38.9%	
Neighborhood					
Dakar	82	75.2%	27	24.8%	0.582
Outside Dakar	37	71.2%	15	28.8%	
Ethnicity					
Wolof	47	78.3%	13	21.7%	0.188
Other	68	68.7%	31	31.3%	
Country of origin					
Senegal	106	73.1%	39	26.9%	0.535*
Other	9	64.3%	5	35.7%	
Marital status					
Single	34	77.3%	10	22.7%	0.578*
Divorced	64	71.9%	25	28.1%	
Widowed	7	63.6%	4	36.4%	
Religion					
Muslim	94	73.4%	34	26.6%	0.767*
Christian	11	68.8%	5	31.3%	
Education					
None	43	69.4%	19	30.6%	0.428
1-6 years	30	81.1%	7	18.9%	
7-14 years	30	71.4%	12	28.6%	
Total children					
0-2	70	78.7%	19	21.3%	0.044
≥3	45	64.3%	25	35.7%	

¹ 200 samples tested: 47 SARS-CoV-2 N positive, 153 SARS-CoV-2 N negative. 159 had baseline record.

*Fisher's exact test was used for variables with cells with observed frequencies ≤5.




Fig. 3. Cross-reactive SARS-CoV-2 cellular responses in samples collected pre-pandemic. PBMCs collected from FSWs prior to the COVID-19 pandemic were stimulated with A) LFn-SARS-CoV-2 S or B) LFn-SARS-CoV-2 N and IFN- γ responses were detected by ELISPOT. SFC, spot forming cells. Black dotted lines, LFn-SARS-CoV-2 S and N cutoffs.




Fig. 4. Evidence for pre-pandemic SARS-CoV-2 variant. Longitudinally collected plasma samples collected from a FSW between 1997 and 2004 were subjected to A) SARS-CoV-2 immunoblots or the commercial B) Mikrogen assay. C) Paired PBMCs samples were stimulated with LFn-SARS-CoV-2 S or LFn-SARS-CoV-2 N and IFN- γ responses were detected by ELISPOT. SFC, spot forming cells. Light blue dotted line, LFn-SARS-CoV-2 S cutoff. Dark blue dotted line, LFn-SARS-CoV-2 N cutoff. D) Plasma neutralization (Log10) of pseudotype virus against SARS CoV-2 Wild type (Wu-1) in one individual with longitudinal samples collected between 1997 and 2004 including two positive controls from SARS CoV-2 infected and vaccinated adults in 2021 and pre-pandemic human sera as negative control. Results displayed under the x-axis correspond to their antibody reactivity via immublot assays.

Supplementary Fig. 1. Overlap in reactivity between hCoV-229E and hCoV-OC43.

		229E				
		S-only	S+N	N-only	Negative	TOTAL
OC43	S-only		1			1
	S+N*		5	1		6
	N-only	2	18	2	3	25
	Negative	5	5		3	13
	TOTAL	7	29	3	6	45

Supplementary Fig. 2. Overlap in reactivity between hCoV-229E S and hCoV-HKU1 S.

		229E				
		S-only	S+N	N-only	Negative	TOTAL
HKU-1 S	Spike-reactive	7	29	3	6	45
	Negative		1		1	2
	TOTAL	7	30	3	7	47

Supplementary Fig. 3. Overlap in reactivity between hCoV-OC43 S and hCoV-HKU1 S.

		OC43				
		S-only	S+N	N-only	Negative	TOTAL
HKU-1 S	Spike-reactive	1	6	25	13	45
	Negative			1	1	2
	TOTAL	1	6	26	14	47